Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations.

Molecular oncology - 1 Dec 2021

Lyskjaer Iben, Davies Christopher, Strobl Anna-Christina, Hindley Joanna, James Steven, Lalam Radhesh K, Cross William, Hide Geoff, Rankin Kenneth S, Jeys Lee, Tirabosco Roberto, Stevenson Jonathan, O'Donnell Paul, Cool Paul, Flanagan Adrienne M

Abstract excerpt

Chondrosarcoma (CS) is a rare tumour type and the most common primary malignant bone cancer in adults. The prognosis, currently based on tumour grade, imaging and anatomical location, is not reliable, and more objective biomarkers are required. We aimed to determine whether the level of circulating tumour DNA (ctDNA) in the blood of CS patients could be used to predict outcome. In this multi-institutional study,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Chondrosarcoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromogranins

Share to Circulating Tumor DNA

Share to GTP-Binding Protein alpha Subunits, Gs

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Risk Assessment

Source

Open in PubMed Open full text

Identifiers

PMID: 34528398
DOI: 10.1002/1878-0261.13102
PMCID: PMC8637565

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations.PMID 34528398Read ↗

Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection.Semantic proximity Read ↗

Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma.Semantic proximity Read ↗

A genetic model for central chondrosarcoma evolution correlates with patient outcome.Semantic proximity Read ↗

IDH1/2 Mutations Predict Shorter Survival in ChondrosarcomaSemantic proximity Read ↗

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.Semantic proximity Read ↗

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.Semantic proximity Read ↗

An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencingSemantic proximity Read ↗

CORR Insights®: Are IDH1 R132 Mutations Associated With Poor Prognosis in Patients With Chondrosarcoma of the Bone?Semantic proximity Read ↗

Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.Semantic proximity Read ↗

Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.Semantic proximity Read ↗

Clinical insights into circulating free-DNA in patients with bone sarcomas and ewing sarcoma.Semantic proximity Read ↗

Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade ChondrosarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.